A Kentucky NP collaborative practice agreement must include specific elements, and the requirements differ for nonscheduled legend drugs (a CAPA‑NS) and for controlled substances (a CAPA‑CS). In general, these agreements must be in writing, reflect required specialty qualifications, outline collaboration and communication, define the scope or limits of prescribing, and be signed by both parties12345.
CAPA‑NS (nonscheduled legend drugs): The agreement must12:
- Be in writing and on the Common CAPA‑NS form.
- Include the name, practice address, phone number, and license number of the APRN and each collaborating physician.
- State the APRN’s population focus and area of practice.
- Indicate that the APRN and collaborating physician are qualified in the same or a similar specialty.
- Define the scope of prescriptive authority for nonscheduled legend drugs.
- Describe the arrangement for collaboration and communication between the APRN and physician regarding prescribing.
- State that it is not a substitute for the exercise of professional judgment.
- Be signed by the APRN and the collaborating physician.
CAPA‑CS (controlled substances): APRNs must use the Board’s standardized Form CAPA‑CS, and the agreement must345:
- Be in writing and signed by the APRN and collaborating physician.
- Show that the APRN and collaborating physician are qualified in the same specialty.
- Describe the arrangement for collaboration and communication between the APRN and physician regarding controlled‑substance prescribing, and include any specific communication requirements.
- State that it is not a substitute for the exercise of professional judgment.
- State any limits on controlled substances that may be prescribed by the APRN, as agreed by the parties (which may be more stringent than statutory or regulatory limits).
Both the CAPA‑NS and Form CAPA‑CS must be reviewed by the APRN and collaborating physician, and any changes to either agreement must be reported to the Board within 30 days6789.